Overview

Bioequivalence of Two Formulations of Parecoxib in Healthy Volunteers Under Fasting Conditions

Status:
NOT_YET_RECRUITING
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of parecoxib after intravenous bolus of parecoxib in healthy volunteers under fasting conditions
Phase:
PHASE4
Details
Lead Sponsor:
Yung Shin Pharm. Ind. Co., Ltd.
Treatments:
parecoxib